BAY 41-2272
Based on 3 publication(s) in Google Scholar
BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research.
For research use only. We do not sell to patients.
- Purity: 99.60%
- CAS No.: 256376-24-6
- Formula: C20H17FN6
- Molecular Weight:360.39
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) BAY 41-2272
More
Biological Activity
BAY 41-2272 (10 μM; 15 min) increases cGMP levels by itself and synergizes with the NO donor SNP (100 μΜ) in A7r5 rat aortic smooth muscle cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hypertensive beagle dogs[2]
-
Dosage:0.3 mg/kg, 1 mg/kg, 3 mg/kg
-
Administration:Oral gavage; single dose; monitored for 12 hr
-
Result:Decreased the mean BP (MBP) in a dose-dependent manner with a decrease of −0.29 ± 5.40 mmHg (p = 0.7960) at the lowest dose of 0.3 mg/kg, −5.51 ± 11.45 mmHg (p = 0.1625) after 1.0 mg/kg and −14.05 ± 1.81 mmHg (p = 0.0042) after 3.0 mg/kg.
Chemical Information
-
CAS No. 256376-24-6
-
Appearance Solid
-
Molecular Weight 360.39
-
Formula C20H17FN6
-
Color White to off-white
-
SMILES
NC1=NC(C2=NN(CC3=CC=CC=C3F)C4=NC=CC=C42)=NC=C1C5CC5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cells
Hepatocyte Thorns, A Novel Drug-Induced Stress Response in Human and Mouse Liver Spheroids. [Abstract]2022 May 10;11(10):1597. PMID: 35626634 -
Eur J Pharmacol
sGC agonist BAY1021189 promotes thoracic aortic dissection formation by accelerating vascular smooth muscle cell phenotype switch. [Abstract]2023 Aug 5:952:175789. PMID: 37244376 -
Am J Physiol Lung Cell Mol Physiol
2014 Jan;306(2):L207-15. PMID: 24242011
Solvent & Solubility
DMSO : 17.5 mg/mL (48.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.75 mg/mL (4.86 mM); Clear solution
This protocol yields a clear solution of ≥ 1.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.75 mg/mL (4.86 mM); Clear solution
This protocol yields a clear solution of ≥ 1.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Makrynitsa GI, et al. Mapping of the sGC Stimulator BAY 41-2272 Binding Site on H-NOX Domain and Its Regulation by the Redox State of the Heme. Front Cell Dev Biol. 2022 Jun 17;10:925457. [Content Brief]
[2]. Vogel J, et al. sGC stimulation lowers elevated blood pressure in a new canine model of resistant hypertension. Hypertens Res. 2021 Dec;44(12):1568-1577. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7748 mL | 13.8739 mL | 27.7477 mL | 69.3693 mL |
| 5 mM | 0.5550 mL | 2.7748 mL | 5.5495 mL | 13.8739 mL | |
| 10 mM | 0.2775 mL | 1.3874 mL | 2.7748 mL | 6.9369 mL | |
| 15 mM | 0.1850 mL | 0.9249 mL | 1.8498 mL | 4.6246 mL | |
| 20 mM | 0.1387 mL | 0.6937 mL | 1.3874 mL | 3.4685 mL | |
| 25 mM | 0.1110 mL | 0.5550 mL | 1.1099 mL | 2.7748 mL | |
| 30 mM | 0.0925 mL | 0.4625 mL | 0.9249 mL | 2.3123 mL | |
| 40 mM | 0.0694 mL | 0.3468 mL | 0.6937 mL | 1.7342 mL |